The increasing use of immunocheckpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immunocheckpoint inhibitors, mainly activated T-cell immunity, may attack normal tissues and organs of the human body and lead to a variety of adverse effects. In the lung, they could induce checkpoint inhibitor associated pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and had a potentially fatal risk if it was not being properly treated. We will summarize the characteristics of CIP and give our advice on how to manage immunocheckpoint inhibitor associated pneumonitis.
【中文题目：免疫检查点抑制剂相关肺炎的临床诊治建议】 【中文摘要：免疫检查点抑制剂在肿瘤中的使用给晚期肿瘤患者带来了新的希望。然而，由免疫检查点抑制剂激活的免疫系统，其中主要是T细胞免疫，可能攻击人体正常组织器官导致相应的免疫毒性反应产生，在肺部可引起免疫检查点抑制剂相关肺炎。这是一类不同于已知肺部间质性肺炎的疾病，如处理不当，有潜在的致命风险。我们将对免疫检查点抑制剂相关肺炎的诊断和治疗给予建议。】 【中文关键词：免疫检查点抑制剂；免疫相关不良反应；检查点抑制剂相关肺炎】.
Keywords: Checkpoint inhibitor pneumonitis; Immune checkpoint inhibitor; Immunotherapy-related toxicities.